Tengteng Wang

Dr. Tengteng Wang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
TWTengteng Wang
Tengteng Wang
MFMaryam Farvid
Maryam Farvid
JKJae Kang
Jae Kang
MHMichelle D. Holmes
Michelle D. Holmes
BRBernard A. Rosner
Bernard A. Rosner
HEHeather Eliassen
Heather Eliassen
Type II diabetes is associated with poor breast cancer prognosis. To study the association between a diabetes risk reduction diet (DRRD) and survival following breast cancer, we followed 8,482 women with breast cancer from two large cohort studies. Information on diet and other factors was repeatedly measured in validated questionnaires every two to four years. The DRRD includes 9 components: higher intakes of cereal fiber, coffee, nuts, whole fruits and polyunsaturated/saturated fat ratio; and lower glycemic index, trans fat, sugar-sweetened beverages, and red meat. Cumulative average DRRD score was calculated using repeated measures of postdiagnostic diet. Deaths were assessed by family members or via National Death Index. Multivariable-adjusted HRs and 95% confidence intervals (CI) were estimated using Cox proportional hazards models. During a median of 14 years of follow-up since diagnosis, 2,600 deaths occurred among participants, 1,042 of which were due to breast cancer. Women with higher postdiagnostic DRRD score had a 20% lower risk of breast cancer–specific mortality (top vs. bottom quintile HR = 0.80; 95% CI = 0.65–0.97; Ptrend = 0.02) and 34% lower risk of all-cause mortality (HR = 0.66; 95% CI = 0.58–0.76; Ptrend < 0.0001). Compared with women who consistently had lower score (≤median) before and after diagnosis, those whose score improved from low to high had a lower risk of breast cancer–specific mortality (HR = 0.77; 95% CI = 0.62–0.95) and overall mortality (HR = 0.85; 95% CI = 0.74–0.97). These findings demonstrate that greater adherence to DRRD was associated with better survival, suggesting postdiagnosis dietary modification consistent with type II diabetes prevention may be important for breast cancer survivors.Significance: This study suggests that greater adherence to the diabetes risk reduction diet after diagnosis associates with improved survival outcomes among a large number of breast cancer survivors.

12 August 2019 in Cancer
Verified
Journal Article
Open access
PDF file
TWTengteng Wang
Tengteng Wang
LMLauren E. McCullough
Lauren E. McCullough
AWAlexandra J. White
Alexandra J. White
PBPatrick T. Bradshaw
Patrick T. Bradshaw
XXXinran Xu
Xinran Xu
MGMarilie D. Gammon
Marilie D. Gammon
Background: The authors hypothesized that epigenetic changes may help to clarify the underlying biologic mechanism linking aspirin use to breast cancer prognosis. To the authors' knowledge, this is the first epidemiologic study to examine whether global methylation and/or tumor promoter methylation of breast cancer‐related genes interact with aspirin use to impact mortality after breast cancer.Methods: Prediagnosis aspirin use was assessed through in‐person interviews within a population‐based cohort of 1508 women diagnosed with a first primary breast cancer in 1996 and 1997. Global methylation in peripheral blood was assessed by long interspersed elements‐1 (LINE‐1) and the luminometric methylation assay. Promoter methylation of 13 breast cancer‐related genes was measured in tumor by methylation‐specific polymerase chain reaction and the MethyLight assay. Vital status was determined by the National Death Index through December 31, 2014 (N = 202/476 breast cancer‐specific/all‐cause deaths identified among 1266 women with any methylation assessment and complete aspirin data). Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs, and the likelihood ratio test was used to evaluate multiplicative interactions.Results: All‐cause mortality was elevated among aspirin users who had methylated promotor of BRCA1 (HR, 1.67; 95% CI, 1.26‐2.22), but not among those with unmethylated promoter of BRCA1 (HR, 0.99; 95% CI, 0.67‐1.45; P for interaction ≤.05). Decreased breast cancer‐specific mortality was observed among aspirin users who had unmethylated promotor of BRCA1 and PR and global hypermethylation of LINE‐1 (HR, 0.60, 0.78, and 0.63, respectively; P for interaction ≤.05), although the 95% CIs included the null.Conclusions: The current study suggests that the LINE‐1 global methylation and promoter methylation of BRCA1 and PR in tumor may interact with aspirin use to influence mortality after breast cancer.

7 March 2018 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
TWTengteng Wang
Tengteng Wang
HPHumberto Parada
Humberto Parada
KMKathleen M. McClain
Kathleen M. McClain
PBPatrick T. Bradshaw
Patrick T. Bradshaw
MTMary Beth Terry
Mary Beth Terry
MGMarilie D. Gammon
Marilie D. Gammon

25 June 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
TWTengteng Wang
Tengteng Wang
PBPatrick T. Bradshaw
Patrick T. Bradshaw
PMPatricia G. Moorman
Patricia G. Moorman
SNSarah J. Nyante
Sarah J. Nyante
HNHazel B. Nichols
Hazel B. Nichols
MGMarilie D. Gammon
Marilie D. Gammon

1 August 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
TWTengteng Wang
Tengteng Wang
YHYujing J. Heng
Yujing J. Heng
GBGabrielle M. Baker
Gabrielle M. Baker
VBVanessa C. Bret-Mounet
Vanessa C. Bret-Mounet
LQLiza M. Quintana
Liza M. Quintana
HEHeather Eliassen
Heather Eliassen
Background: The relationships between PTEN loss and/or PIK3CA mutation and breast cancer prognosis remain controversial. We aim to examine the associations in large epidemiologic cohorts. Methods: We followed women with invasive breast cancer from the Nurses’ Health Studies with available data on tumor PTEN expression (n = 4,111) and PIK3CA mutation (n = 2,930). PTEN expression was evaluated by IHC and digitally scored (0%–100%). Pyrosequencing of six hotspot mutations of PIK3CA was performed. Results: We found loss of PTEN expression (≤10%) occurred in 17% of cases, and PIK3CA mutations were detected in 11% of cases. After adjusting for clinical and lifestyle factors, PTEN loss was not associated with worse breast cancer-specific mortality among all samples [HR, 0.85; 95% confidence intervals (CI), 0.71–1.03] or among estrogen receptor (ER)-positive tumors (HR, 0.99; 95% CI, 0.79–1.24). However, among ER-negative tumors, PTEN loss was associated with lower breast cancer-specific mortality (HR, 0.68; 95% CI, 0.48–0.95). PIK3CA mutation was not strongly associated with breast cancer-specific mortality (HR, 0.89; 95% CI, 0.67–1.17). Compared with tumors without PTEN loss and without PIK3CA mutation, those with alterations (n = 540) were not at higher risk (HR, 1.07; 95% CI, 0.86–1.34). However, women with both PTEN loss and PIK3CA mutation (n = 38) were at an increased risk of breast cancer-specific mortality (HR, 1.65; 95% CI, 0.83–3.26). Conclusions: In this large epidemiologic study, the PTEN-mortality association was more pronounced for ER-negative tumors, and the joint PTEN loss and PIK3CA mutation may be associated with worse prognosis. Impact: Further studies with a larger sample of ER-negative tumors are needed to replicate our findings and elucidate underlying mechanisms.

22 March 2024 in International Journal of Cancer
Verified
Journal Article
Open access
TWTengteng Wang
Tengteng Wang
BCBoyang Chai
Boyang Chai
WCWendy Y. Chen
Wendy Y. Chen
MHMichelle D. Holmes
Michelle D. Holmes
JEJennifer Erdrich
Jennifer Erdrich
AEA. Heather Eliassen
A. Heather Eliassen
We aimed to examine the association between the use of metformin and other anti‐diabetic medications and breast cancer incidence within two large prospective cohort studies. We followed 185,181 women who participated in the Nurses' Health Study (NHS; 1994–2016) and the NHSII (1995–2017), with baseline corresponding to the date metformin was approved for type 2 diabetes (T2D) treatment in the US Information on T2D diagnosis, anti‐diabetes medications, and other covariates was self‐reported at baseline and repeatedly assessed by follow‐up questionnaires every 2 years. Breast cancer cases were self‐reported and confirmed by medical record review. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between medication use and breast cancer were estimated using Cox proportional hazards regression models, adjusting for breast cancer risk factors. During 3,324,881 person‐years of follow‐up, we ascertained 9,192 incident invasive breast cancer cases, of which 451 were among women with T2D. Compared with women without T2D (n = 169,263), neither metformin use (HR = 0.97; 95% CI = 0.81–1.15) nor other anti‐diabetic medications use (HR = 1.11; 95% CI = 0.90–1.36) associated with significantly lower breast cancer incidence. Among women with T2D (n = 15,918), compared with metformin never users, metformin ever use was not significantly inversely associated with breast cancer (HR = 0.92; 95% CI = 0.74–1.15). Although we observed that past use of metformin was inversely associated with breast cancer in the T2D population (HR = 0.67; 95% CI = 0.48–0.94), current use (HR = 1.01; 95% CI = 0.80–1.27) and longer duration of metformin use were not associated with breast cancer (each 2‐year interval: HR = 1.01; 95% CI = 0.95–1.07). Overall, metformin use was not associated with the risk of developing breast cancer among the overall cohort population or among women with T2D.